Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
The Factor XII test measures the activity of Factor XII, a protein made by your liver that helps start the intrinsic pathway of blood clotting. It becomes active when blood comes into contact with certain surfaces, setting off a cascade that leads to clot formation in laboratory assays.
Your clinician may order this test when your activated partial thromboplastin time (aPTT) is prolonged, to determine whether the cause is a deficiency of this specific factor. Unlike some other clotting factor deficiencies, Factor XII deficiency typically does not cause abnormal bleeding. The test is performed on a blood sample collected in a citrate tube and is usually reported as activity relative to normal plasma.
Knowing your Factor XII activity helps clarify the reason for a prolonged aPTT and guides next steps in evaluation. A low result often points to a hereditary deficiency or an acquired reduction, while a normal result can redirect attention to other causes such as inhibitors or medications. This information helps avoid unnecessary treatments and supports accurate diagnosis.
This test is used with other studies, such as mixing studies and testing for other factors or inhibitors, to build a complete picture of your clotting system. While Factor XII deficiency is not linked to a bleeding tendency, it can affect how other tests look, which can be important before procedures or when evaluating unexplained lab results.
If your Factor XII activity is low, your healthcare team will consider whether this reflects a lifelong, inherited condition or a temporary or acquired change. Many people with low Factor XII have no bleeding problems, and management often focuses on documenting the finding and understanding its impact on other tests. Your clinician may repeat testing, check other clotting factors, or perform mixing studies to confirm the result.
If your activity is higher than expected, it may reflect physiologic changes such as inflammation or hormone exposure. Your clinician will interpret the result in the context of your medications, medical history, and other coagulation tests. Follow-up depends on your overall clinical picture, not the lab number alone.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Underfilled or overfilled citrate tubes, high hematocrit, or difficult draws can dilute or concentrate plasma and yield falsely low or high Factor XII activity.
Residual heparin from lines, unfractionated heparin therapy, or some direct oral anticoagulants can interfere with clot-based assays and mimic low activity.
Acute phase responses, estrogen therapy, and pregnancy can shift clotting factor levels and may modestly increase Factor XII activity.
Antiphospholipid antibodies and specific factor inhibitors can prolong clotting times and complicate interpretation of factor assays.
Because Factor XII is made in the liver, significant liver disease, severe illness, or disseminated intravascular activation can alter measured activity.
Inherited Factor XII deficiency is often detected after an unexpectedly prolonged aPTT and may be confirmed with repeat testing and family studies.
References